Skip to main content

Table 1 Drug repositioning candidates for Melanoma. Drugs showing a negative correlation score less than or equal to − 0.40 and affecting more than 50% of the dysregulated pathways in melanoma. The last column outlines the current uses of the given drug in other conditions according to DrugBank and scientific literature

From: PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures

DrugDrugBank IDCorrelation ScoreAffected Pathways (%)Description
CrizotinibDB08865−0.6474.07Used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
OlmesartanDB00275−0.8555.56Used for the treatment of hypertension.
Sepantronium−0.2174.07Clinical trials in advanced non-small-cell lung cancer.
BortezomibDB00188−0.5262.96Used for the treatment of multiple myeloma.
FluspirileneDB04842−0.555.56Used for the treatment of schizophrenia.
VistusertibDB11925−0.4466.67Under investigation for the treatment of Advanced Gastric Adenocarcinoma.
OlaparibDB09074−0.4466.67A poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of Ovarian and Breast Cancer.
TivozanibDB11800−0.4466.67Used in trials for the treatment of solid tumors, Ovarian Cancer, Glioblastoma, Prostate Cancer among others.
BelinostatDB05015−0.4355.56Used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).